1Lansky A J, Hochman JS, Ward PA, et al. Percutaneous coronary intervention and adjunctive pharmaeot herapy in women: a statement for healthcare professionals from the American Heart Association [J]. Circulation, 2005, 111(7):940-953.
6Argulian E, Patel AD, Abramson JL, et al. Gender differences in short-term cardiovascular outcomes after percutaneous coronary interventions[J]. Am J Cardiol, 2006, 98( 1 ) :48 -53.
7Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the national heart, lung, and blood institute-sponsored women's isehemia syndrome evaluation ( WISE ) [ J ]. Circulation, 2004, 109(6) :726 -732.
8von Meting GO, Arant CB, Wessel TR, et al. Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the national heart, lung, and blood institutesponsored women' s ischemia syndrome evaluation (WISE) [ J ]. Circulation, 2004, 109 (6) :722 - 725.
7Choussat R,Montalescot G,Collet JP,et al.A unique,low dose of intravenous enoxaparin in elective percutaneous coronary intervention[J].J Am Coll Cardiol,2002,40(11):1943-1950.
8Kereiakes DJ,Grines C,Fry E,et al.Enoxaparin and abciximab adjunctive pharmaco-therapy during percutaneous coronary intervention[J].J Invasive Cardiol,2001,13(4):272-278
9Goodman SG,Fitchett D,Armstrong PW,et al.Randomized evaluation of the safety and efficacy of enoxaparin versus unfractiona-ted heparin in high-risk patients with non-ST-segment elevation acute coronary syndrom-es receiving the glycoprotein Ⅱb/Ⅲa inhibitor eptifibatide[J].Circulation,2003,107(2):238-244.
